Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.8M
-
Number of holders
-
82
-
Total 13F shares, excl. options
-
47.8M
-
Shares change
-
+843K
-
Total reported value, excl. options
-
$1.08B
-
Value change
-
+$18.5M
-
Put/Call ratio
-
0.24
-
Number of buys
-
38
-
Number of sells
-
-37
-
Price
-
$22.68
Significant Holders of Theravance Biopharma, Inc. - Common Stock (TBPH) as of Q2 2018
98 filings reported holding TBPH - Theravance Biopharma, Inc. - Common Stock as of Q2 2018.
Theravance Biopharma, Inc. - Common Stock (TBPH) has 82 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 47.8M shares
of 49.8M outstanding shares and own 96.06% of the company stock.
Largest 10 shareholders include Woodford Investment Management Ltd (11.2M shares), BAUPOST GROUP LLC/MA (9.31M shares), FMR LLC (8.08M shares), BlackRock Inc. (3.75M shares), VANGUARD GROUP INC (3.55M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.74M shares), Cormorant Asset Management, LP (1.3M shares), ARMISTICE CAPITAL, LLC (1.18M shares), STATE STREET CORP (877K shares), and NORGES BANK (800K shares).
This table shows the top 82 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.